Recent Advances in NIR-II Fluorescence Imaging-Based Cancer Treatment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 1477
Special Issue Editor
Interests: polymer chemistry; molecular imaging probes; nanomedicines; prodrugs; aggregation-induced emission; fluorescence imaging; photoacoustic imaging; microscopy; wide-field imaging; two photon imaging; second harmonic imaging
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
NIR-II (Near-Infrared II) fluorescence imaging has emerged as a promising tool for advancing cancer theranostics, particularly in drug delivery. This innovative approach involves utilizing the unique optical properties of NIR-II light, which penetrates biological tissues more effectively than visible wavelengths. By employing NIR-II fluorescence imaging, researchers can visualize and track drug delivery processes with unprecedented depth and clarity, enhancing precision in cancer theranostics. Integrating NIR-II fluorescence imaging into drug delivery systems allows real-time monitoring of therapeutic agents, enabling dynamic assessments of their distribution, pharmacokinetics, pharmacodynamics, and overall efficacy within the tumor microenvironment. Apart from this, NIR-II fluorescence can be combined with other imaging modalities, which could be useful for different biomedical applications. In reality, NIR-II fluorescence imaging-guided drug delivery holds great promise for improving the accuracy and efficiency of cancer theranostics, accompanying a new era of personalized and targeted cancer treatment strategies.
Dr. Bing Guo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NIR-II (Near-Infrared II) fluorescence
- cancer theranostics
- drug delivery
- targeted cancer treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
